View in EDS

High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B

Saved in:
Bibliographic Details
Title: High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
Authors: Wong, VWS, Chan, HLY, Sung, JJY, Chan, FKL, Chu, ESH, Chan, HY, Wong, GLH, Cheng, ASL, Yu, J, Ng, EKO
Source: International Journal of Cancer. 124:2766-2770
Publisher Information: Wiley, 2009.
Publication Year: 2009
Subject Terms: Male, 0301 basic medicine, Hepatitis B virus, Carcinoma, Hepatocellular, Case-control studies, Hepatitis B, Chronic - blood - virology, Sensitivity and Specificity, 03 medical and health sciences, Hepatitis B, Chronic, Liver neoplasms, Predictive Value of Tests, Risk Factors, Biomarkers, Tumor, Humans, False Positive Reactions, Chronic - blood - virology, Carcinoma, Hepatocellular - blood - virology, Hepatocellular - blood - virology, Neoplasm Staging, 0303 health sciences, Interleukin-6, Carcinoma, Liver Neoplasms, Middle Aged, Hepatitis B, Interleukin-6 - blood, Prognosis, Fibrosis, Liver Neoplasms - blood - virology, 3. Good health, Case-Control Studies, Hepatitis B virus - isolation and purification, Cytokines, Female
Description: Increased interleukin‐6 (IL‐6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL‐6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case‐control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty‐seven patients developed HCC at a median follow‐up of 62 months (interquartile range: 41–110). Serum IL‐6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL‐6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL‐6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL‐6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high‐risk patients for HCC surveillance program. © 2009 UICC
Document Type: Article
Language: English
ISSN: 1097-0215
0020-7136
DOI: 10.1002/ijc.24281
Access URL: https://pubmed.ncbi.nlm.nih.gov/19267406
https://pubmed.ncbi.nlm.nih.gov/19267406/
http://www.ncbi.nlm.nih.gov/pubmed/19267406
https://onlinelibrary.wiley.com/doi/10.1002/ijc.24281
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.24281
http://hub.hku.hk/handle/10722/92203
https://core.ac.uk/display/37919854
http://hdl.handle.net/10722/92203
Rights: Wiley Online Library User Agreement
Accession Number: edsair.doi.dedup.....1d4eca9a7f29f09c06715b9a491b71cc
Database: OpenAIRE
Description
Abstract:Increased interleukin‐6 (IL‐6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL‐6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case‐control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty‐seven patients developed HCC at a median follow‐up of 62 months (interquartile range: 41–110). Serum IL‐6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL‐6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL‐6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL‐6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high‐risk patients for HCC surveillance program. © 2009 UICC
ISSN:10970215
00207136
DOI:10.1002/ijc.24281